Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1237–1245. doi: 10.1128/aac.41.6.1237

Attenuation of gentamicin-induced nephrotoxicity in rats by fleroxacin.

D Beauchamp 1, G Laurent 1, L Grenier 1, P Gourde 1, J Zanen 1, J A Heuson-Stiennon 1, M G Bergeron 1
PMCID: PMC163893  PMID: 9174177

Abstract

The effect of fleroxacin on gentamicin-induced nephrotoxicity was evaluated with female Sprague-Dawley rats. Animals were injected during 4 or 10 days with saline (NaCl; 0.9%), gentamicin alone at doses of 10 and 40 mg/kg of body weight/12 h (subcutaneously), fleroxacin alone at a dose of 25 mg/kg/12 h (intraperitoneally), or the combination gentamicin-fleroxacin in the same regimen. Gentamicin induced a dose- and time-dependent renal toxicity as evaluated by gentamicin cortical levels, sphingomyelinase activity in the renal cortex, histopathologic and morphometric analysis, blood urea nitrogen and serum creatinine levels, and cellular regeneration ([3H]thymidine incorporation into DNA of cortical cells). The extent of these changes was significantly reduced when gentamicin was given in combination with fleroxacin. Although the mechanisms by which fleroxacin reduces the nephrotoxic potential of gentamicin are unknown, we propose that the fleroxacin-gentamicin combination enhances exocytosis activity in proximal tubular cells, as suggested by the higher excretion of urinary enzymes and lower cortical levels of gentamicin observed in animals treated with the combination fleroxacin-gentamicin compared with those treated with gentamicin alone. The protective effect of fleroxacin on gentamicin nephrotoxicity should be investigated further.

Full Text

The Full Text of this article is available as a PDF (610.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyama H., Inoue M., Mitsuhashi S. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone. J Antimicrob Chemother. 1988 Oct;22 (Suppl 500):99–114. doi: 10.1093/jac/22.supplement_d.99. [DOI] [PubMed] [Google Scholar]
  2. Barrett J. F., Gootz T. D., McGuirk P. R., Farrell C. A., Sokolowski S. A. Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother. 1989 Oct;33(10):1697–1703. doi: 10.1128/aac.33.10.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beauchamp D., Gourde P., Bergeron M. G. Subcellular distribution of gentamicin in proximal tubular cells, determined by immunogold labeling. Antimicrob Agents Chemother. 1991 Nov;35(11):2173–2179. doi: 10.1128/aac.35.11.2173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beauchamp D., Laurent G., Maldague P., Abid S., Kishore B. K., Tulkens P. M. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther. 1990 Nov;255(2):858–866. [PubMed] [Google Scholar]
  5. Beauchamp D., Pellerin M., Gourde P., Pettigrew M., Bergeron M. G. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother. 1990 Jan;34(1):139–147. doi: 10.1128/aac.34.1.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beauchamp D., Thériault G., Grenier L., Gourde P., Perron S., Bergeron Y., Fontaine L., Bergeron M. G. Ceftriaxone protects against tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1994 Apr;38(4):750–756. doi: 10.1128/aac.38.4.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bergeron M. G. The pharmacokinetics and tissue penetration of the fluoroquinolones. Clin Invest Med. 1989 Feb;12(1):20–27. [PubMed] [Google Scholar]
  8. Bloch R., Luft F. C., Rankin L. I., Sloan R. S., Yum M. N., Maxwell D. R. Protection from gentamicin nephrotoxicity by cephalothin and carbenicillin. Antimicrob Agents Chemother. 1979 Jan;15(1):46–49. doi: 10.1128/aac.15.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Christ W., Lehnert T., Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S141–S146. doi: 10.1093/clinids/10.supplement_1.s141. [DOI] [PubMed] [Google Scholar]
  10. Couture M., Simard M., Gourde P., Lessard C., Gurnani K., Lin L., Carrier D., Bergeron M. G., Beauchamp D. Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin. Antimicrob Agents Chemother. 1994 Apr;38(4):742–749. doi: 10.1128/aac.38.4.742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. English J., Gilbert D. N., Kohlhepp S., Kohnen P. W., Mayor G., Houghton D. C., Bennett W. M. Attenuation of experimental tobramycin nephrotoxicity by ticarcillin. Antimicrob Agents Chemother. 1985 Jun;27(6):897–902. doi: 10.1128/aac.27.6.897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Felmingham D., Robbins M. J., O'Hare M. D., Jones K., Ridgway G., Grüneberg R. N. In vitro activity and synergy studies with fleroxacin. J Chemother. 1989 Jul;1(4 Suppl):162–164. [PubMed] [Google Scholar]
  13. Fischman A. J., Livni E., Babich J. W., Alpert N. M., Bonab A., Chodosh S., McGovern F., Kamitsuka P., Liu Y. Y., Cleeland R. Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. Antimicrob Agents Chemother. 1996 Mar;40(3):659–664. doi: 10.1128/aac.40.3.659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Callahan R. J., Correia J. A. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. Antimicrob Agents Chemother. 1992 Oct;36(10):2286–2292. doi: 10.1128/aac.36.10.2286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W. Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob Agents Chemother. 1993 Oct;37(10):2144–2152. doi: 10.1128/aac.37.10.2144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gilbert D. N., Wood C. A., Kohlhepp S. J., Kohnen P. W., Houghton D. C., Finkbeiner H. C., Lindsley J., Bennett W. M. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis. 1989 May;159(5):945–953. doi: 10.1093/infdis/159.5.945. [DOI] [PubMed] [Google Scholar]
  17. Giuliano R. A., Paulus G. J., Verpooten G. A., Pattyn V. M., Pollet D. E., Nouwen E. J., Laurent G., Carlier M. B., Maldague P., Tulkens P. M. Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int. 1984 Dec;26(6):838–847. doi: 10.1038/ki.1984.226. [DOI] [PubMed] [Google Scholar]
  18. Giurgea-Marion L., Toubeau G., Laurent G., Heuson-Stiennon J. A., Tulkens P. M. Impairment of lysosome-pinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses. Toxicol Appl Pharmacol. 1986 Nov;86(2):271–285. doi: 10.1016/0041-008x(86)90058-x. [DOI] [PubMed] [Google Scholar]
  19. Haller I. Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob Agents Chemother. 1985 Nov;28(5):663–666. doi: 10.1128/aac.28.5.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hoshino K., Sato K., Une T., Osada Y. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob Agents Chemother. 1989 Oct;33(10):1816–1818. doi: 10.1128/aac.33.10.1816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hussy P., Maass G., Tümmler B., Grosse F., Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986 Jun;29(6):1073–1078. doi: 10.1128/aac.29.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kirchhoff L. V., Gam A. A., Gilliam F. C. American trypanosomiasis (Chagas' disease) in Central American immigrants. Am J Med. 1987 May;82(5):915–920. doi: 10.1016/0002-9343(87)90152-5. [DOI] [PubMed] [Google Scholar]
  23. Kojima R., Ito M., Suzuki Y. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (3). Protective effect of latamoxef against tobramycin nephrotoxicity and its protective mechanism. Jpn J Pharmacol. 1986 Nov;42(3):397–404. doi: 10.1254/jjp.42.397. [DOI] [PubMed] [Google Scholar]
  24. Kusajima H., Ishikawa N., Machida M., Uchida H., Irikura T. Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother. 1986 Aug;30(2):304–309. doi: 10.1128/aac.30.2.304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Laurent G., Carlier M. B., Rollman B., Van Hoof F., Tulkens P. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem Pharmacol. 1982 Dec 1;31(23):3861–3870. doi: 10.1016/0006-2952(82)90303-3. [DOI] [PubMed] [Google Scholar]
  26. Laurent G., Maldague P., Carlier M. B., Tulkens P. M. Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats. Antimicrob Agents Chemother. 1983 Oct;24(4):586–593. doi: 10.1128/aac.24.4.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Luft F. C., Rankin L. I., Sloan R. S., Yum M. N. Recovery from aminoglycoside nephrotoxicity with continued drug administration. Antimicrob Agents Chemother. 1978 Sep;14(3):284–287. doi: 10.1128/aac.14.3.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Maruhn D. Rapid colorimetric assay of beta-galactosidase and N-acetyl-beta-glucosaminidase in human urine. Clin Chim Acta. 1976 Dec;73(3):453–461. doi: 10.1016/0009-8981(76)90147-9. [DOI] [PubMed] [Google Scholar]
  29. Neu H. C., Chin N. X. In vitro activity of fleroxacin in combination with other antimicrobial agents. Am J Med. 1993 Mar 22;94(3A):9S–16S. [PubMed] [Google Scholar]
  30. Neu H. C. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):255–261. doi: 10.1007/BF01966998. [DOI] [PubMed] [Google Scholar]
  31. Nightingale C. H. Overview of the pharmacokinetics of fleroxacin. Am J Med. 1993 Mar 22;94(3A):38S–43S. [PubMed] [Google Scholar]
  32. Nonclercq D., Wrona S., Toubeau G., Zanen J., Heuson-Stiennon J. A., Schaudies R. P., Laurent G. Tubular injury and regeneration in the rat kidney following acute exposure to gentamicin: a time-course study. Ren Fail. 1992;14(4):507–521. doi: 10.3109/08860229209047660. [DOI] [PubMed] [Google Scholar]
  33. Patterson D. R. Quinolone toxicity: methods of assessment. Am J Med. 1991 Dec 30;91(6A):35S–37S. doi: 10.1016/0002-9343(91)90308-k. [DOI] [PubMed] [Google Scholar]
  34. Persijn J. P., van der Slik W. A new method for the determination of gamma-glutamyltransferase in serum. J Clin Chem Clin Biochem. 1976 Sep;14(9):421–427. doi: 10.1515/cclm.1976.14.1-12.421. [DOI] [PubMed] [Google Scholar]
  35. Rohner P., Herter C., Auckenthaler R., Pechère J. C., Waldvogel F. A., Lew D. P. Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species. Antimicrob Agents Chemother. 1989 Dec;33(12):2037–2041. doi: 10.1128/aac.33.12.2037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Silverblatt F. J., Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 1979 Apr;15(4):335–345. doi: 10.1038/ki.1979.45. [DOI] [PubMed] [Google Scholar]
  37. Stuck A. E., Kim D. K., Frey F. J. Fleroxacin clinical pharmacokinetics. Clin Pharmacokinet. 1992 Feb;22(2):116–131. doi: 10.2165/00003088-199222020-00003. [DOI] [PubMed] [Google Scholar]
  38. Thibault N., Grenier L., Simard M., Bergeron M. G., Beauchamp D. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob Agents Chemother. 1994 May;38(5):1027–1035. doi: 10.1128/aac.38.5.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Toubeau G., Nonclercq D., Zanen J., Lambricht P., Tulkens P. M., Heuson-Stiennon J. A., Laurent G. Distribution of epidermal growth factor in the kidneys of rats exposed to amikacin. Kidney Int. 1991 Oct;40(4):691–699. doi: 10.1038/ki.1991.262. [DOI] [PubMed] [Google Scholar]
  40. Wood C. A., Finkbeiner H. C., Kohlhepp S. J., Kohnen P. W., Gilbert D. N. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob Agents Chemother. 1989 Aug;33(8):1280–1285. doi: 10.1128/aac.33.8.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES